Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Cash: 2010-2025

Historic Change in Cash for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $25.7 million.

  • Iovance Biotherapeutics' Change in Cash rose 139.78% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year increase of 96.06%. This contributed to the annual value of -$59.3 million for FY2024, which is 4.26% down from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Change in Cash stood at $25.7 million, which was up 164.80% from -$39.6 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Change in Cash's 5-year high stood at $311.8 million during Q1 2023, with a 5-year trough of -$253.5 million in Q2 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Change in Cash value was -$39.6 million (recorded in 2025), while the average stood at -$6.7 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Change in Cash crashed by 271.22% in 2024, and later skyrocketed by 237.58% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Change in Cash (Quarterly) stood at -$152.8 million in 2023, then soared by 68.27% to -$48.5 million in 2024, then spiked by 139.78% to $25.7 million in 2025.
  • Its Change in Cash stands at $25.7 million for Q3 2025, versus -$39.6 million for Q2 2025 and $56.0 million for Q1 2025.